🇺🇸 Camostat mesylate in United States
60 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 60
Most-reported reactions
- Off Label Use — 8 reports (13.33%)
- Interstitial Lung Disease — 7 reports (11.67%)
- Renal Impairment — 7 reports (11.67%)
- Diarrhoea — 6 reports (10%)
- Malignant Neoplasm Progression — 6 reports (10%)
- Pancreatitis Acute — 6 reports (10%)
- Cerebral Infarction — 5 reports (8.33%)
- Covid-19 — 5 reports (8.33%)
- Dyspnoea — 5 reports (8.33%)
- Nausea — 5 reports (8.33%)
Other Infectious Disease / Virology approved in United States
Frequently asked questions
Is Camostat mesylate approved in United States?
Camostat mesylate does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Camostat mesylate in United States?
Seoul National University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.